^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Pancreatic Adenocarcinoma
    Regimen:FOLFIRINOX (5-fluorouracil + irinotecan + leucovorin calcium + oxaliplatin)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Preferred Regimens...Only for known BRCA1/2 or PALB2 mutations...FOLFIRINOX or modified FOLFIRINOX…
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes.

    Published date:
    05/19/2021
    Excerpt:
    Several somatic abnormalities were noted in tumors (BRCA2, TP53, and mismatch-repair genes)…There was a OS benefit to FOLFOX or FOLFIRINOX chemotherapy compared to gemcitabine or capecitabine-based regimens (p = 0.006)...The use of FOLFOX or FOLFIRINOX chemotherapy regimens was associated with improved OS in metastatic patients.